8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Johnson & Johnson filed an 8‑K (Item 9.01) with a press release dated Jan 21, 2026 for the period ended…
Filed with the SEC on · Summarized by InvestorsBot
Johnson & Johnson filed an 8‑K (Item 9.01) with a press release dated Jan 21, 2026 for the period ended Dec 28, 2025. Earnings release available as Exhibit 99.1. $JNJ 📢 #earnings #pharma
Exhibit 99.2 contains unaudited comparative supplementary sales data and a condensed consolidated Statement of Earnings for fiscal Q4 and full year (period ended Dec 28, 2025) — key revenue/profit detail for investors. $JNJ 📊 #financials #earnings
Exhibit 104: cover page filed in Inline XBRL. Report signed Jan 21, 2026 by Controller Robert J. Decker, Jr., confirming filing formality and machine‑readable financials. $JNJ 🖊️ #SECfiling #transparency